Bioventus (NASDAQ:BVS) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Bioventus (NASDAQ:BVS) to a strong-buy rating in a research note released on Wednesday,Zacks.com reports.

Several other equities research analysts also recently weighed in on BVS. Weiss Ratings reissued a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Barrington Research raised Bioventus to a “strong-buy” rating in a research report on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Bioventus currently has an average rating of “Buy”.

Bioventus Stock Performance

Shares of BVS stock opened at $8.41 on Wednesday. The company has a market capitalization of $696.01 million, a price-to-earnings ratio of 25.48 and a beta of 0.78. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.14 and a current ratio of 1.74. Bioventus has a one year low of $5.81 and a one year high of $11.25. The company’s 50-day moving average is $8.12 and its 200 day moving average is $7.49.

Bioventus (NASDAQ:BVS) last issued its earnings results on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.02. The business had revenue of $157.90 million during the quarter. Bioventus had a net margin of 4.00% and a return on equity of 29.99%.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.